Neurovalens Secures £6m Investment to Boost Global Expansion

Deal News | Aug 19, 2025 | Clarendon Fund Managers Limited

Neurovalens, a Belfast-based medical device firm, has secured a £6m investment round led by the Investment Fund for Northern Ireland (IFNI), managed by Clarendon Fund Managers Limited. This substantial financial boost aims to accelerate the commercial expansion of the company’s FDA-cleared products, Modius Sleep and Modius Calm, which address insomnia and anxiety, respectively. The funding, which came from both new and existing investors, including Whiterocks Growth Capital Fund and a host of private investors, will be used for the advancement in the US and global healthcare markets, as well as for advancing regulatory processes and expanding the product portfolio. The UK-based neurostimulation technology company has raised approximately £20m to date for its pioneering efforts in addressing global health challenges through non-invasive methods. The IFNI seeks to fill financial gaps and spur economic growth in Northern Ireland by supporting innovative and scaling businesses across various sectors.

Sectors

Medical Devices
Private Equity & Venture Capital

Geography

Northern Ireland, UK – Neurovalens is based in Belfast, Northern Ireland, and the Investment Fund for Northern Ireland is involved in the funding.
United States – Neurovalens plans to expand its market presence in the US with its FDA-cleared medical devices.

Industry

Medical Devices – Neurovalens operates within the Medical Devices sector, with a focus on neurostimulation technologies for health issues like insomnia and anxiety.
Private Equity & Venture Capital – Clarendon Fund Managers, alongside various other investors, are involved in funding and developing growth opportunities in Neurovalens.

Financials

£6m – Total investment secured in the recent funding round led by IFNI for Neurovalens.
£1.5m – Investment by the Investment Fund for Northern Ireland (IFNI) in Neurovalens.
£1m – Loan provided by the IFNI debt fund managed by Whiterock to Neurovalens.
£780,000 – Investment by Whiterocks Growth Capital Fund in Neurovalens.
£20m – Total funds raised by Neurovalens to date, through equity and debt.

Participants

Name	Role	Type	Description
Neurovalens	Target company	Company	A medical device firm specializing in neuroscience and non-invasive medical devices for health conditions such as insomnia and anxiety.
Clarendon Fund Managers Limited	Fund Manager	Company	Manages the Investment Fund for Northern Ireland and provided leadership in the recent funding round for Neurovalens.
Investment Fund for Northern Ireland (IFNI)	Investor	Company	Led the funding round for Neurovalens, providing £1.5m in investment and a £1m loan through their debt fund.
Whiterocks Growth Capital Fund	Investor	Company	Provided £780,000 in investment as part of the recent Neurovalens funding round.
British Business Bank	Investor/Supporter	Company	Launched the IFNI and aims to support economic growth in Northern Ireland through innovation.
Dr. Jason McKeown	CEO	Person	Co-founder and CEO of Neurovalens, leading the company on its expansion and innovation efforts.
Brian Cummings	Investment Director	Person	Investment Director at Clarendon Fund Managers, involved in the funding and expansion strategy of Neurovalens.